Anup Ramachandran

University of Kansas Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (28)

Year:

2026

Year:

2026

Acetaminophen (APAP) overdose is a leading cause of acute liver failure, and the inadequacy of the current antidote N‐acetylcysteine motivates the search for newer therapeutic interventions. This is facilitated by the replication of human pathophysiology by the mouse model, with the C57BL/6 strain being most used. While variations in susceptibility to liver injury between the C57BL/6(J) and (N) substrains are well recognized, substrain influence on the innate immune response and regenerative outcomes which influence development of acute liver failure are unknown. We compared these aspects temporally between 6J and 6N mice following a 300 mg/kg APAP overdose. Consistent with prior findings, 6N mice exhibited higher liver injury compared to 6J mice. Neutrophil and macrophage infiltration followed similar patterns, but with different temporal dynamics, with 6J mice showing a rapid but transient response, while 6N mice exhibited delayed and prolonged immune activity. Importantly, these immune dynamics were accompanied by delayed regeneration and sustained p21 expression, indicating impaired regeneration in 6N mice. Taken together, both substrains displayed broadly similar immune behavior in terms of cytokine expression and cell recruitment patterns, with the delayed immune resolution and regeneration observed in 6N mice being reflective of the extent of injury rather than intrinsic differences in immune function. Thus, our study emphasizes the need to evaluate multiple time points to fully capture the evolving nature of liver injury and recovery during APAP hepatotoxicity. It also underscores the importance of clearly considering and reporting mouse substrain and vendor, as these factors can significantly shape experimental outcomes and may explain discrepancies between studies using this clinically relevant model.

Year:

2025

New Approach Methodologies (NAMs), including organoids, microphysiological systems, and computer modeling, are gaining increased popularity for toxicological testing and even mechanistic research. With the use of human cells, the primary objectives of NAMs are to develop more human-relevant test systems and to reduce, and ultimately eliminate, animal experiments. There are many advantages of using NAMs for biological research. For example, NAMs can be used to test the dose- and time-dependent toxicity of numerous chemicals and mixtures in a cost-effective way and reduce animal use. Although these are worthwhile goals when considering the big picture, the problems lie in the details. First, in vivo insight is needed to build and refine NAMs, including computer modeling. Second, primary human cells are difficult to obtain reliably and in sufficient quantities; substitutes such as immortalized cell lines or induced pluripotent stem cells have the advantage of being more robust and available in unlimited numbers, but their basal and stress-induced gene expression profiles are quite different compared with primary cells. Third, critical aspects such as metabolic competency, the presence of various cell types in an organ, spatial aspects, oxygen gradients, and the role of inflammatory cells are very difficult to replicate in vitro. Therefore, in vivo experiments are necessary to verify results obtained with NAMs. Importantly, the results of both NAMs and the in vivo animal experiments need to be translatable to human disease processes. The advantages and limitations of NAMs are being discussed using the challenges of investigating mechanisms of drug hepatotoxicity as an example.

Year:

2025

Cisplatin is an effective chemotherapeutic drug for the treatment of bladder cancer, though cisplatin-induced nephrotoxicity (CIN) occurs in ∼20% to 30% of patients, limiting its clinical use. Evidence has shown that cytochrome P450 2E1 (CYP2E1), a drug metabolism enzyme expressed in proximal tubules, mediates the production of reactive oxygen species during cisplatin-induced injury. Previously, we showed that the repurposed drug 4-methylpyrazole (4MP) blocks CYP2E1 activity. Here, we investigated the potential protective effects of 4MP against CIN. Male and female C57BL/6J mice were treated intraperitoneally (i.p.) with a single 20 mg/kg dose of cisplatin for 3 days or 9 mg/kg/wk for 4 wk with or without 50 mg/kg 4MP as a co-treatment. Our findings revealed that acute treatment with cisplatin induced severe histological tubular damage and elevated plasma BUN and creatinine levels in male but not female mice. This difference correlated with higher basal CYP2E1 expression in the kidneys of male mice compared with female mice. We also found that cisplatin increased renal CYP2E1 activity and that inhibition of CYP2E1 with 4MP significantly reduced cisplatin-induced cell death in male mice and primary normal human kidney cells. By contrast, human bladder cancer cells do not express CYP2E1, and treatment with 4MP did not interfere with cisplatin’s anticancer effects in human bladder cancer HTB9 cells. This study highlights the critical role of CYP2E1 in CIN and suggests that its inhibition with 4MP in the kidney is a potential prophylactic therapeutic option to prevent CIN in bladder cancer patients without affecting its antineoplastic effect.

Year:

2025

An overdose of acetaminophen (APAP) is the leading cause of drug-induced hepatotoxicity and acute liver failure in the United States. It is established that the predominant mode of hepatocyte cell death after an APAP overdose is through necrosis, and it is now recognized that this occurs through regulated pathways involving RIP kinases. These kinases, along with the pseudo-kinase MLKL, are central players in classical necroptotic cell death. Despite the skepticism regarding the role of necroptosis in APAP-induced liver injury, recent research demonstrating necroptosis-independent roles for MLKL led us to re-examine the role of this pseudo-kinase in APAP pathophysiology. Treatment of Mlkl−/− mice with a moderate (300 mg/kg) overdose of APAP resulted in an exacerbation of liver injury at 6- and 12-h post-APAP as evidenced by elevated plasma alanine aminotransferase activities, and extensive necrosis accompanied by diminished glutathione levels. Interestingly, these differences between Mlkl−/− and wild-type mice were negated at the 24-h mark, previously scrutinized by others. At 6 and 12 h post-APAP, Mlkl−/− mice exhibited augmented translocation of AIF and Endonuclease G without affecting JNK activation, suggesting enhanced mitochondrial permeability transition in the absence of MLKL. Lack of MLKL also impacted autophagy, the unfolded protein response and endoplasmic reticulum stress, with decreased levels of p62 and LC3B and increased expression of CHOP and GRP78 at 6 h post-APAP. In essence, our findings illuminate a noncanonical role for MLKL in the early phases of APAP-induced liver injury, warranting further exploration of its influence on APAP pathophysiology.

Year:

2025

Acetaminophen (APAP)-induced liver injury and acute liver failure is a significant clinical problem worldwide; in addition, APAP overdoses in animals or in cell culture are used as popular models to study drug-induced liver injury mechanisms and test therapeutic interventions. Early assumptions that APAP toxicity is caused by a single mechanism resulting in a defined mode of cell death in hepatocytes had to be questioned when over the years many different mechanisms and modes of cell death were reported. Although many of the contradictory results and conclusions reported over the years can be attributed to lack of understanding of established mechanisms, methodological problems, and misinterpretation of data, it is increasingly recognized that some of the reported differences in signaling mechanisms and even a switch in the mode of cell death can be caused by variations in the experimental conditions. In this review, examples will be discussed how experimental conditions (dose, solvent, etc.), the experimental system (species, strain, and substrain in vivo, cell type, and in vitro conditions), and also adaptive responses and off-target effects of genetic manipulations and chemical interventions, can impact the mechanisms of cell death. Given that the conditions will determine the results, it is therefore of critical importance to keep in mind the translational aspect of the experiments, i.e., the conditions relevant to the human pathophysiology. Only the full appreciation of these issues will lead to reproducible and clinically relevant results that advance our understanding of all facets of the human pathophysiology and identify clinically relevant therapeutic targets.

Year:

2025

Year:

2025

Acetaminophen (APAP) overdose is the leading cause of acute liver failure (ALF) in the United States, with many patients rapidly progressing to hyperacute liver failure. Although hepatocytes are the main target of APAP toxicity, endothelial cells (ECs) are also affected. However, the efficacy of an endothelial-specific biomarker to predict patient outcomes remains unknown. This study aimed to evaluate angiopoietin-2 (ANGPT2) as a prognostic biomarker for poor outcomes in APAP-induced ALF. Using human and mouse single-cell RNA-sequencing data, we found that ANGPT2 expression was significantly elevated in ECs following APAP exposure. We measured circulating ANGPT2 levels in 2 independent APAP-ALF cohorts: A cohort from Phoenix (n = 43) and the ALF Study Group (n = 80). In the Phoenix cohort, ANGPT2 levels were significantly higher in nonsurvivors with an area under the receiver-operating characteristic curve of 0.938. In the ALF Study Group cohort, we stratified patients based on time of symptom onset, finding that ANGPT2 had improved prognostic value in early-presenting patients, with Day 1 and 3 AUC values of 0.825 and 0.918, respectively. Lastly, we combined the patient cohorts (n = 110), finding that ANGPT2 alone or in combination with Model for End-Stage Liver Disease (MELD) score outperformed MELD alone based on AUC (ANGPT2: 0.87, MELD: 0.83, ANGPT2+MELD: 0.90). Conclusions: ANGPT2 is a promising prognostic biomarker for APAP-induced ALF, reflecting endothelial stress and offering superior predictive value compared with MELD alone, especially in early-presenting patients. Its capacity for predicting poor outcomes underscores its value in improving patient prognosis and therapeutic intervention strategies in APAP overdose cases.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (5)

Constantine Karvellas

Professor

University of Alberta

CANADA
View details

Darren Wallace

Director

University of Kansas Medical Center

UNITED STATES
View details

David Umbaugh

Postdoctoral Associate

Duke University

UNITED STATES
View details

Hartmut Jaeschke

University Distinguished Professor

University of Kansas Medical Center

UNITED STATES
View details

Julia Laskin

Professor

Purdue University

UNITED STATES
View details